Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-11-22
2010-06-08
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S578000, C540S579000
Reexamination Certificate
active
07732437
ABSTRACT:
The invention concerns a novel histamine receptor antagonist and the use of an histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemida, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. The novel compounds comprise compounds according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-α]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. Also claimed is the novel use of commercially available histamine H1-and H2-receptor antagonists for the reduction of intracranial pressure (ICP).
REFERENCES:
patent: 6218381 (2001-04-01), Janssens et al.
patent: 6251894 (2001-06-01), Janssens et al.
patent: 2004/0167138 (2004-08-01), Janssens et al.
patent: 0 675 889 (1995-10-01), None
patent: WO 94/13681 (1994-06-01), None
patent: WO 97/24350 (1997-07-01), None
patent: WO 97/34897 (1997-09-01), None
patent: 1999/13871 (1999-03-01), None
patent: 02/100862 (2002-12-01), None
patent: WO 03/44023 (2003-05-01), None
Engelborghs, K., et al,Temporal changes in intracranial pressure in a modified experimental model of closed head injury, J. Neurosurg,89: 796-806; 1998.
Engelborghs, K., et al.,Impaired autoregulation of cerebral blood flow in an experimental model of traumatic brain injury, J. Neurotrauma, 17(8): 667-677, 2000.
Jain, K.K.,Chapter4:Neuroprotection in Acute Trauma, 'Neuroprotection in Cns Disorders: Commercial Opportunities'. A Jain PharmaBiotech Report: 65-73, 2000.
Mohanty, et al.,Journal of the Neurological Sciences, 1989, 90:87-97.
Stella, V.J., et al., “Prodrugs: the control of drug delivery via bioreversible chemical modification”, 1980, pp. 112-176,.
Stella, V.J., et al., “Prodrugs: Do They Have Advantages in Clinical Practice?” 1985, 29: pp. 455-473.
Van Rossem, K., et al,Brain oxygenation after experimental closed head injury, Adv. Exp. Med. Biol.471: 209-215, 1999.
Hungarian Novelty Search Report for corresponding Application No. HUP0402357.
Letter dated Oct. 8, 2009 regarding Hungarian Search Report.
International Search Report mailed Mar. 5, 2003,for corresponding Application No. PCT/EP02/13180.
Alcázar-Vaca Manuel Jesús
Bartolomé-Nebreda José Manuel
Fernández-Gadea Francisco Javier
Gómez-Sánchez Antonio
Janssens Frans Eduard
Coleman Brenda L
Janssen Pharmaceutica NV.
LandOfFree
Use of anti-histaminics for acute reduction of elevated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-histaminics for acute reduction of elevated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-histaminics for acute reduction of elevated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4206296